FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Phase 2
Completed
NCT04768686
| Condition | Gastric Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
|---|
| Status | Completed |
|---|
| Enrollment | 20 participants |
|---|
| Interventions | FLX475, Pembrolizumab |
|---|
| Start date | May 18, 2021 |
|---|
| Completion date | Aug 12, 2024 |
|---|
| Results posted | Sep 25, 2025 |
|---|
Summary
This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. This study is designed to assess the potential anti-tumor activity when administered at the 100mg QD of FLX475 with pembrolizumab and will be conducted (2) cohorts as detailed below. * Cohort 1: EBV negative / CPI naïve gastric cancer subjects who have progressed on at least 2 prior systemic treatments for advanced or metastatic gastric cancer * Cohort 2: EBV positive / CPI naïve gastric cancer subjects who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer Approximately 90 subjects may be enrolled across two cohorts to examine the safety and efficacy.
Overall Response Rate (ORR) in Subjects Treated With FLX475 in Combination With Pembrolizumab
Initial assessment performed after the first 2 cycles, then every 2 cycles for the first year, followed by every 3 cycles thereafter for up to 2 years and at any time per investigator's discretion and at ED/EOT, up to 2 years. · percentage of participants
| Cohort 1: EBV Negative / CPI naïve Gastric Cancer | 0 percentage of participants |
|---|
| Cohort 2: EBV Positive / CPI naïve Gastric Cancer | 60.0 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.